Osteoporosis is a prevalent disease with unmet therapeutic needs. Whether the anti-sclerostin antibody romosozumab can offer an effective improvement in osteoporosis treatment outcomes in postmenopausal women was the central question addressed by the meta-analysis presented below.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
